Building Your Evidence-Based Hair Protocol: The Clinical Decision Stack

There is no single optimal AGA protocol — there is a first-line evidence base, an adjunctive evidence tier, and a set of clinical variables that determine which combination is right for a given individual. This article walks through the clinical decision framework.

The evidence base for AGA treatment is larger and more internally consistent than most men receive guidance on. This article presents the treatments in order of evidence strength and provides a framework for assembling an individual protocol — not a generic recommendation, but a decision structure that incorporates the clinical variables that actually determine outcomes.

Tier 1: Established, guideline-supported treatments

Finasteride 1mg (oral, daily): Pivotal RCT evidence (Merck PLESS trials, 1997). DHT suppression 65–70%. Anagen extension, hair count increase, density preservation over 5-year follow-up. Side effect profile established over 25+ years. First-line for most men with AGA.

Topical minoxidil 5% (once or twice daily): Pivotal RCT evidence. SULT1A1-dependent responder rate approximately 60–70%. Perifollicular vasodilation, anagen extension, hair count increase. Independent mechanism from finasteride — combination is additive.

Combination of both: Head-to-head evidence confirms combination superiority over either monotherapy for hair count and density endpoints. This is the evidence-supported standard for most men wanting maximum pharmacological effect from Tier 1 options.

Tier 2: Alternatives and escalations

Dutasteride 0.5mg (off-label for AGA): Greater DHT suppression (90–95%) than finasteride. Superior efficacy in head-to-head comparisons. Rational choice when finasteride response is inadequate after 12+ months, or when aggressive AGA in a young man warrants maximum pharmacological DHT suppression from the outset.

Oral minoxidil 0.5–2.5mg: Effective in SULT1A1 non-responders to topical minoxidil. Systemic exposure — dose must be calibrated for cardiovascular tolerability. Growing evidence base from multiple open-label and controlled series showing hair density benefit.

Tier 3: Evidence-supported adjuncts

Ketoconazole 2% shampoo (2–3x weekly): Addresses Malassezia-driven microinflammation, provides local anti-androgenic activity via type 1 5-AR inhibition and AR antagonism. Low cost, low risk, adjunctive benefit established in small controlled studies.

Low-level laser therapy (LLLT): FDA-cleared for AGA. Multiple RCTs showing hair count improvement. Mechanism involves mitochondrial photobiomodulation in follicle cells. Modest absolute effect size; effective as adjunct in combination protocols.

PRP (platelet-rich plasma): Procedural adjunct with growing RCT evidence. Growth factors in platelet-rich plasma (PDGF, VEGF, IGF-1) stimulate papilla cell activity. Multiple controlled studies show hair density improvement, though standardisation of preparation protocols varies between centres.

What the evidence does not support

Monotherapy with any botanical supplement (saw palmetto, pumpkin seed oil, rosemary oil) as a substitute for finasteride in progressing AGA. These may be low-risk adjuncts; they are not evidence-equivalent alternatives for men with active pattern progression where each month of suboptimal treatment represents irreversible follicle loss.

The clinical decision framework — evidence tier 1 first, escalate based on response, add adjuncts with coherent mechanisms — provides the scaffold. Individual clinical variables determine the assembly within that scaffold.